Updates are available Correction dated 2024-06-06
Click to view Correction: https://doi.org/10.1038/s41586-024-07646-z
Updates are available Correction dated 2024-04-22
Click to view Correction: https://doi.org/10.1038/s41586-024-07413-0
-
Authors
Koeberl, Dwight
Schulze, Andreas https://orcid.org/0000-0001-8491-1095
Sondheimer, Neal https://orcid.org/0000-0001-9982-5712
Lipshutz, Gerald S. https://orcid.org/0000-0001-7876-6776
Geberhiwot, Tarekegn https://orcid.org/0000-0002-3629-2338
Li, Lerong
Saini, Rajnish
Luo, Junxiang
Sikirica, Vanja
Jin, Ling
Liang, Min https://orcid.org/0000-0001-7162-4070
Leuchars, Mary https://orcid.org/0009-0006-7251-6630
Grunewald, Stephanie https://orcid.org/0000-0003-2861-8200
- License Information
-
More Information
Article History
Received: 9 August 2023
Accepted: 1 March 2024
First Online: 3 April 2024
Change Date: 6 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-024-07646-z
Change Date: 22 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-024-07413-0
Competing interests
: D.K. is a consultant for Amicus, Genzyme Sanofi, Sangamo Therapeutics, Takeda and Vertex; is a grant support recipient from Amicus, Genzyme Sanofi, Roivant Rare Diseases and Viking Therapeutics; and has equity in AskBio–Bayer. A.S. is an investigator and consultant for Moderna, Ultragenyx and iEcure; and is a consultant and/or advisory board member for Aeglea, Beam, Ceres Brain, Horizon, iEcure, MTPharma, Recordati and Satellite Bio. N.S. was an investigator and consultant for Moderna at the time of the study and is a current employee of Synlogic. G.S.L. has research grants from Moderna and has served as a consultant for Audentes Therapuetics, Taysha Therapeutics and Tenaya Therapeutics. T.G. is an investigator for Moderna. L.L., R.S., J.L., V.S., L.J. and M. Liang are employees of Moderna and hold stock or stock options in the company. At the time of the study, M. Leuchars was an employee of Moderna and held stock or stock options in the company. S.G. is an investigator, consultant, advisory board member and recipient of travel reimbursements for Moderna, and consults for BridgeBio, Glycomine, Jaguar, Orphazyme and Ultragenyx.
